Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $230

Benzinga Newsdesk www.benzinga.com Positive 92.8%

Neg 0% Neu 0% Pos 92.8%

Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $220 to $230.